Volume 23 (2020)
Volume 22 (2019)
Volume 21 (2018)
Volume 20 (2017)
Volume 19 (2016)
Volume 18 (2015)
Volume 17 (2014)
Volume 16 (2013)
Volume 15 (2012)
Volume 14 (2011)
Volume 13 (2010)
Volume 12 (2009)
Volume 11 (2008)
Volume 10 (2007)
Volume 9 (2006)
Volume 8 (2005)
Volume 7 (2004)
Volume 6 (2002)
Volume 5 (2002)
Volume 4 (2000)
Volume 3 (1999)
Volume 2 (1998)
Volume 1 (1997)
1. Lupoid leishmaniasis: A case report

Hamideh Moravvej; Maryam Yousefi; Behrooz Barikbin

Volume 9, suppl.1 , 2006, , Pages 6-6

Abstract
  Lupoid leishmaniasis is an unusual complication of acute cutaneous leishmaniasis which can represent a diagnostic and therapeutic challenge. The disease is actually a reactivation of an earlier acute cutaneous infection. It usually starts close to or in the scar of previous lesion and can cause severe ...  Read More

2. Frequency of resistance to systemically administered Meglumine Antimoniate (Glucantime) in patients with acute cutaneous Leishmaniasis: A cross-sectional study

MA Nilfroush Zadeh; N Anasri; R Derakhshan

Volume 8, Issue 6 , 2006, , Pages 457-461

Abstract
  Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied ...  Read More

4. A comparison between intralesional hypertonic Sodium Chloride solution and Meglumine Antimoniate (Glucantime) injections in the treatment of cutaneous Leishmaniasis

G Sadeghian; MA Nilforoush Zadeh; M Motevali Emami

Volume 8, Issue 4 , 2005, , Pages 251-255

Abstract
  Background and objective: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis, but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance and adverse effects, efforts to find ...  Read More